JP2023541011A5 - - Google Patents
Info
- Publication number
- JP2023541011A5 JP2023541011A5 JP2023515183A JP2023515183A JP2023541011A5 JP 2023541011 A5 JP2023541011 A5 JP 2023541011A5 JP 2023515183 A JP2023515183 A JP 2023515183A JP 2023515183 A JP2023515183 A JP 2023515183A JP 2023541011 A5 JP2023541011 A5 JP 2023541011A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- group
- cmet
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063075702P | 2020-09-08 | 2020-09-08 | |
| US63/075,702 | 2020-09-08 | ||
| PCT/US2021/049310 WO2022055893A1 (en) | 2020-09-08 | 2021-09-07 | Pharmaceutical combination and tumor treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541011A JP2023541011A (ja) | 2023-09-27 |
| JP2023541011A5 true JP2023541011A5 (enExample) | 2024-09-17 |
| JP7900368B2 JP7900368B2 (ja) | 2026-08-04 |
Family
ID=80629827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515183A Active JP7900368B2 (ja) | 2020-09-08 | 2021-09-07 | 医薬組み合わせおよび腫瘍治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250017921A1 (enExample) |
| EP (1) | EP4210704B1 (enExample) |
| JP (1) | JP7900368B2 (enExample) |
| AU (1) | AU2021339579A1 (enExample) |
| CA (1) | CA3191363A1 (enExample) |
| IL (1) | IL300952A (enExample) |
| MX (1) | MX2023002757A (enExample) |
| WO (1) | WO2022055893A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313361A (en) * | 2021-12-06 | 2024-08-01 | Ideaya Biosciences Inc | Combined treatment that includes a fax inhibitor and a c-met inhibitor |
| WO2024044775A1 (en) * | 2022-08-26 | 2024-02-29 | Ideaya Biosciences, Inc. | Methods of treating uveal melanoma |
| WO2024220839A1 (en) * | 2023-04-21 | 2024-10-24 | Ideaya Biosciences, Inc. | Methods of treating hepatic-only metastatic uveal melanoma |
| WO2025240628A1 (en) * | 2024-05-15 | 2025-11-20 | Ideaya Biosciences, Inc. | Processes for preparing a pkc inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100267742A1 (en) | 2009-04-17 | 2010-10-21 | Rush University Medical Center | Combination targeted therapy for lung cancer |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| AU2012267888A1 (en) * | 2011-06-07 | 2014-01-30 | Caris Mpi, Inc. | Molecular profiling for cancer |
| EA023521B1 (ru) * | 2011-11-14 | 2016-06-30 | Сефалон, Инк. | ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ |
| WO2014174478A1 (en) | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
| JO3589B1 (ar) * | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| FI3681503T3 (fi) | 2017-09-12 | 2026-08-13 | Novartis Ag | Proteiinikinaasi C:n estäjiä uveamelanooman hoitoon |
| RS67265B1 (sr) | 2019-01-07 | 2025-10-31 | Ideaya Biosciences Inc | Lečenje kancera koji ima gnaq ili gna11 genetske mutacije sa inhibitorima protein kinaze c |
-
2021
- 2021-09-07 CA CA3191363A patent/CA3191363A1/en active Pending
- 2021-09-07 WO PCT/US2021/049310 patent/WO2022055893A1/en not_active Ceased
- 2021-09-07 JP JP2023515183A patent/JP7900368B2/ja active Active
- 2021-09-07 EP EP21867451.3A patent/EP4210704B1/en active Active
- 2021-09-07 AU AU2021339579A patent/AU2021339579A1/en active Pending
- 2021-09-07 MX MX2023002757A patent/MX2023002757A/es unknown
- 2021-09-07 IL IL300952A patent/IL300952A/en unknown
- 2021-09-07 US US18/043,298 patent/US20250017921A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230210852A1 (en) | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 | |
| Ilson et al. | A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus | |
| Sheng et al. | GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis | |
| ES2529790T3 (es) | Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB | |
| ES2874875T3 (es) | Procedimiento de tratamiento de adenocarcinoma de pulmón | |
| TW202136252A (zh) | 化合物及其用途 | |
| Vízkeleti et al. | The role of CCND1 alterations during the progression of cutaneous malignant melanoma | |
| JP6761798B2 (ja) | タンパク質キナーゼ阻害剤に対する感受性予測用組成物、キット、及び方法 | |
| JP2018526324A (ja) | がんの診断および処置の方法 | |
| Ha et al. | Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma | |
| Bircan et al. | EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study | |
| Andea et al. | Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status | |
| AU2026200456A1 (en) | Treatment of canine cancers | |
| ES3054788T3 (en) | Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors | |
| JP6465790B2 (ja) | Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法 | |
| Wang et al. | Clinicopathologic features and molecular spectrum of spindle cell and sclerosing rhabdomyosarcomas in the head and neck region | |
| KR20230087445A (ko) | Aml의 치료 요법 및 rara 작용제, 저메틸화제, 및 bcl-2 억제제의 용도 | |
| WO2005075681A1 (ja) | 抗癌剤に対する癌細胞の感受性を検定する方法 | |
| Gao et al. | Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals | |
| Que et al. | New strategy for antimetastatic treatment of lung cancer: a hypothesis based on circulating tumour cells | |
| JP7747459B2 (ja) | Ｆｇｆｒ阻害薬に対する感受性の判定方法 | |
| Jaramillo et al. | Gastrointestinal stromal tumors (GISTs): role of CD 117 and PDGFRA Golgi-like staining pattern in the recognition of mutational status | |
| Bang et al. | Recent trends (1991-2010) of metastatic skin cancers in Korea | |
| Zhao et al. | CPNE7 promotes colorectal tumorigenesis by interacting with NONO to initiate ZFP42 transcription | |
| He et al. | Relationship between gene mutations and protein expressions of PDGFR α and C-kit in gastrointestinal stromal tumors |